Evidence map›Paper›PMID 32995780›Full record

ArticlebioRxiv : the preprint server for biology2020

Baricitinib treatment resolves lower airway inflammation and neutrophil recruitment in SARS-CoV-2-infected rhesus macaques.

Timothy N Hoang, Maria Pino, Arun K Boddapati, Elise G Viox, Carly E Starke, Amit A Upadhyay, Sanjeev Gumber, Kathleen Busman-Sahay, Zachary Strongin, Justin L Harper and 33 more

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 5 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

43 authors at 5 institutions in 1 country.

Timothy N HoangDivision of Microbiology and Immunology, Yerkes National Primate Research Center, Emory University, Atlanta, Georgia, USA.
Maria PinoDivision of Microbiology and Immunology, Yerkes National Primate Research Center, Emory University, Atlanta, Georgia, USA.
Arun K BoddapatiYerkes Genomics Core Laboratory, Yerkes National Primate Research Center, Emory University, Atlanta, Georgia, USA.
Elise G VioxDivision of Microbiology and Immunology, Yerkes National Primate Research Center, Emory University, Atlanta, Georgia, USA.
Carly E StarkeVaccine and Gene Therapy Institute, Oregon Health & Science University, Beaverton, OR, USA.
Amit A UpadhyayYerkes Genomics Core Laboratory, Yerkes National Primate Research Center, Emory University, Atlanta, Georgia, USA.
Sanjeev GumberDepartment of Pathology and Laboratory Medicine, School of Medicine, Emory University, Atlanta, Georgia, USA.
Kathleen Busman-SahayVaccine and Gene Therapy Institute, Oregon Health & Science University, Beaverton, OR, USA.
Zachary StronginDivision of Microbiology and Immunology, Yerkes National Primate Research Center, Emory University, Atlanta, Georgia, USA.
Justin L HarperDivision of Microbiology and Immunology, Yerkes National Primate Research Center, Emory University, Atlanta, Georgia, USA.
Gregory K TharpYerkes Genomics Core Laboratory, Yerkes National Primate Research Center, Emory University, Atlanta, Georgia, USA.
Kathryn L PellegriniYerkes Genomics Core Laboratory, Yerkes National Primate Research Center, Emory University, Atlanta, Georgia, USA.
Shannon KirejczykDivision of Pathology, Yerkes National Primate Research Center, Emory University, Atlanta, Georgia, USA.
Keivan ZandiCenter for AIDS Research, Department of Pediatrics, School of Medicine, Emory University, Atlanta, Georgia, USA.
Sijia TaoCenter for AIDS Research, Department of Pediatrics, School of Medicine, Emory University, Atlanta, Georgia, USA.
Tristan R HortonYerkes Genomics Core Laboratory, Yerkes National Primate Research Center, Emory University, Atlanta, Georgia, USA.
Elizabeth N BeagleYerkes Genomics Core Laboratory, Yerkes National Primate Research Center, Emory University, Atlanta, Georgia, USA.
Ernestine A MaharDivision of Microbiology and Immunology, Yerkes National Primate Research Center, Emory University, Atlanta, Georgia, USA.
Michelle Yh LeeDivision of Microbiology and Immunology, Yerkes National Primate Research Center, Emory University, Atlanta, Georgia, USA.
Joyce CohenDivision of Animal Resources, Yerkes National Primate Research Center, Emory University, Atlanta, Georgia, USA.
Sherrie M JeanDivision of Animal Resources, Yerkes National Primate Research Center, Emory University, Atlanta, Georgia, USA.
Jennifer S WoodDivision of Animal Resources, Yerkes National Primate Research Center, Emory University, Atlanta, Georgia, USA.
Fawn Connor-StroudDivision of Animal Resources, Yerkes National Primate Research Center, Emory University, Atlanta, Georgia, USA.
Rachelle L StammenDivision of Animal Resources, Yerkes National Primate Research Center, Emory University, Atlanta, Georgia, USA.
Olivia M DelmasDivision of Microbiology and Immunology, Yerkes National Primate Research Center, Emory University, Atlanta, Georgia, USA.
Shelly WangDivision of Microbiology and Immunology, Yerkes National Primate Research Center, Emory University, Atlanta, Georgia, USA.
Kimberly A CooneyDepartment of Medicine, School of Medicine, Emory University, Atlanta, Georgia, USA.
Michael N SayeghDepartment of Medicine, School of Medicine, Emory University, Atlanta, Georgia, USA.
Lanfang WangDepartment of Medicine, School of Medicine, Emory University, Atlanta, Georgia, USA.
Daniela WeiskopfCenter for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, CA, USA.
Peter D FilevDepartment of Radiology and Imaging Sciences, School of Medicine, Emory University, Atlanta, Georgia, USA.
Jesse WaggonerDepartment of Medicine, School of Medicine, Emory University, Atlanta, Georgia, USA.
Anne PiantadosiDepartment of Medicine, School of Medicine, Emory University, Atlanta, Georgia, USA.
Sudhir P KasturiDivision of Microbiology and Immunology, Yerkes National Primate Research Center, Emory University, Atlanta, Georgia, USA.
Hilmi Al-ShakhshirDepartment of Pathology, Case Western Reserve University, Cleveland, OH, USA.
Susan P RibeiroDepartment of Pathology, Case Western Reserve University, Cleveland, OH, USA.
Rafick P SekalyDepartment of Pathology, Case Western Reserve University, Cleveland, OH, USA.
Rebecca D LevitDepartment of Medicine, School of Medicine, Emory University, Atlanta, Georgia, USA.
Jacob D EstesVaccine and Gene Therapy Institute, Oregon Health & Science University, Beaverton, OR, USA.
Thomas H VanderfordDivision of Microbiology and Immunology, Yerkes National Primate Research Center, Emory University, Atlanta, Georgia, USA.
Raymond F SchinaziCenter for AIDS Research, Department of Pediatrics, School of Medicine, Emory University, Atlanta, Georgia, USA.
Steven E BosingerDivision of Microbiology and Immunology, Yerkes National Primate Research Center, Emory University, Atlanta, Georgia, USA.
Mirko PaiardiniDivision of Microbiology and Immunology, Yerkes National Primate Research Center, Emory University, Atlanta, Georgia, USA.
Emory University · USCase Western Reserve University · USOregon Health & Science University · USLa Jolla Institute for Immunology · USOregon National Primate Research Center · US

Funding

Upgrade of confocal microscopy at the Oregon National Primate Research CenterP51OD011092 · OD · OREGON HEALTH & SCIENCE UNIVERSITY · PI Bonnie J. Nagel · 2012 to 2026
$203.9M
Yerkes National Primate Research Center Role of type-I IFN in regulating COVID-19 induced inflammation and pathogenesisP51OD011132 · OD · EMORY UNIVERSITY · PI Joon Sup Lee · 2012 to 2026
$167.0M
Virology and Molecular Biomarkers CoreP30AI050409 · NIAID · EMORY UNIVERSITY · PI Carlos del Rio · 2002 to 2026
$74.0M
Harnessing IL-10 in cART treated SIV infected macaques to restore immunity and to eradicate HIVR37AI141258 · NIAID · EMORY UNIVERSITY · PI Rafick Pierre Sekaly · 2018 to 2026
$7.8M
Simultaneous antigen receptor repertoire profiling and single-cell transcriptomics in T and B lymphocytes from limited clinical samplesU24AI120134 · NIAID · EMORY UNIVERSITY · PI BOSINGER, STEVEN EDWARD · 2015 to 2024
$6.5M
Immune based interventions for HIV eradicationR01AI116379 · NIAID · EMORY UNIVERSITY · PI PAIARDINI, MIRKO · 2015 to 2019
$4.2M
Defining Mechanisms of Viral Persistence in Situ at the Single-Cell LevelR01AI149672 · NIAID · OREGON HEALTH & SCIENCE UNIVERSITY · PI ESTES, JACOB D · 2020 to 2024
$4.0M
Novel ISH Approaches to Quantify Replication Competent ReservoirsR01AI143411 · NIAID · OREGON HEALTH & SCIENCE UNIVERSITY · PI ESTES, JACOB D · 2019 to 2023
$3.6M
Towards Suppression and Elimination of HIV in the CNSR01MH116695 · NIMH · EMORY UNIVERSITY · PI SCHINAZI, RAYMOND FELIX, TYOR, WILLIAM R · 2018 to 2022
$3.4M
Illumina NovaSeq 6000 High Throughput DNA Sequencer for Emory UniversityS10OD026799 · OD · EMORY UNIVERSITY · PI BOSINGER, STEVEN EDWARD · 2019 to 2019
$985k
Slide Scanner for the ONPRC Imaging and Morphology CoreS10OD025002 · OD · OREGON HEALTH & SCIENCE UNIVERSITY · PI SRINIVASAN, SATHYA · 2018 to 2018
$146k
NIAID NIH HHS P30 AI050409NIAID NIH HHS R01 AI116379NIAID NIH HHS R01 AI143411NIAID NIH HHS R01 AI149672NIAID NIH HHS R37 AI141258NIAID NIH HHS U24 AI120134NIH HHS P51 OD011092NIH HHS P51 OD011132NIH HHS S10 OD025002NIH HHS S10 OD026799NIMH NIH HHS R01 MH116695
6 · The paper itself

Abstract

Effective therapeutics aimed at mitigating COVID-19 symptoms are urgently needed. SARS-CoV-2 induced hypercytokinemia and systemic inflammation are associated with disease severity. Baricitinib, a clinically approved JAK1/2 inhibitor with potent anti-inflammatory properties is currently being investigated in COVID-19 human clinical trials. Recent reports suggest that baricitinib may also have antiviral activity in limiting viral endocytosis. Here, we investigated the immunologic and virologic efficacy of baricitinib in a rhesus macaque model of SARS-CoV-2 infection. Viral shedding measured from nasal and throat swabs, bronchoalveolar lavages and tissues was not reduced with baricitinib. Type I IFN antiviral responses and SARS-CoV-2 specific T cell responses remained similar between the two groups. Importantly, however, animals treated with baricitinib showed reduced immune activation, decreased infiltration of neutrophils into the lung, reduced NETosis activity, and more limited lung pathology. Moreover, baricitinib treated animals had a rapid and remarkably potent suppression of alveolar macrophage derived production of cytokines and chemokines responsible for inflammation and neutrophil recruitment. These data support a beneficial role for, and elucidate the immunological mechanisms underlying, the use of baricitinib as a frontline treatment for severe inflammation induced by SARS-CoV-2 infection.

Identifiers

PMID32995780
PMCPMC7523106
OpenAlexW3087387495

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.